Below are the most recent publications written about "Response Evaluation Criteria in Solid Tumors" by people in Profiles.
-
Kuon Yeng Escalante CM, Siu Xiao T, Nagaraj RU, Savsani E, Mohammed A, Li J, Lyshchik A, Liu JB, Wessner CE, Tahmasebi A, Soulen MC, Kono Y, Eisenbrey JR. Evaluation of the Contrast-Enhanced Ultrasound Nonradiation Treatment Response Assessment LI-RADS v2024 Using Data From a Multi-Center Transarterial Chemoembolization Study. Acad Radiol. 2024 12; 31(12):5078-5086.
-
Brose MS, Panaseykin Y, Konda B, de la Fouchardiere C, Hughes BGM, Gianoukakis AG, Joo Park Y, Romanov I, Krzyzanowska MK, Leboulleux S, Binder TA, Dutcus C, Xie R, Taylor MH. A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer. J Clin Endocrinol Metab. 2022 02 17; 107(3):776-787.
-
Mehnert JM, Varga A, Brose MS, Aggarwal RR, Lin CC, Prawira A, de Braud F, Tamura K, Doi T, Piha-Paul SA, Gilbert J, Saraf S, Thanigaimani P, Cheng JD, Keam B. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer. BMC Cancer. 2019 Mar 04; 19(1):196.
-
Huang RY, Unadkat P, Bi WL, George E, Preusser M, McCracken JD, Keen JR, Read WL, Olson JJ, Seystahl K, Le Rhun E, Roelcke U, Koeppen S, Furtner J, Weller M, Raizer JJ, Schiff D, Wen PY. Response assessment of meningioma: 1D, 2D, and volumetric criteria for treatment response and tumor progression. Neuro Oncol. 2019 02 14; 21(2):234-241.
-
Wirth LJ, Tahara M, Robinson B, Francis S, Brose MS, Habra MA, Newbold K, Kiyota N, Dutcus CE, Mathias E, Guo M, Sherman SI, Schlumberger M. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT). Cancer. 2018 06 01; 124(11):2365-2372.
-
Dogan BE, Yuan Q, Bassett R, Guvenc I, Jackson EF, Cristofanilli M, Whitman GJ. Comparing the Performances of Magnetic Resonance Imaging Size vs Pharmacokinetic Parameters to Predict Response to Neoadjuvant Chemotherapy and Survival in Patients With Breast Cancer. Curr Probl Diagn Radiol. 2019 May - Jun; 48(3):235-240.
-
Ocean AJ, Starodub AN, Bardia A, Vahdat LT, Isakoff SJ, Guarino M, Messersmith WA, Picozzi VJ, Mayer IA, Wegener WA, Maliakal P, Govindan SV, Sharkey RM, Goldenberg DM. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics. Cancer. 2017 Oct 01; 123(19):3843-3854.
-
Hyman DM, Sill MW, Lankes HA, Piekarz R, Shahin MS, Ridgway MR, Backes F, Tenney ME, Mathews CA, Hoffman JS, Aghajanian C, Hensley ML. A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D. Gynecol Oncol. 2017 Jan; 144(1):96-100.